Kozieł Sandra, Wojtala Daria, Barzowska-Gogola Agata, Pucelik Barbara, Waglewska Ewelina, Siczek Miłosz, Witwicki Maciej, Niorettini Alessandro, Kyzioł Agnieszka, Malik Magdalena, Bazylińska Urszula, Błaszczak Ewa, Komarnicka Urszula K
Faculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, Poland.
Łukasiewicz Research Network, Kraków Institute of Technology, 30-418 Kraków, Poland.
J Med Chem. 2025 Jul 24;68(14):14442-14464. doi: 10.1021/acs.jmedchem.5c00486. Epub 2025 Jul 9.
This study reports the synthesis, characterization, and biological evaluation of four novel heteronuclear Ru(II)-Cu(II) complexes with phosphine-fluoroquinolone conjugates. Structural analysis using X-ray diffraction, density functional theory calculations, and various spectroscopic techniques confirmed the stability and coordination geometries. The cytotoxicity was evaluated in vitro across multiple cancer cell lines (lung, breast, pancreatic, prostate) and noncancerous cells. In vivo toxicity was also assessed using a zebrafish () larvae model. The results demonstrated that Ru(II)-Cu(II) complexes exhibit greater anticancer activity compared with cisplatin while almost being nontoxic toward control cells in vitro. Mechanistic studies revealed that their action involves nuclei accumulation, reactive oxygen species generation, lipid peroxidation, and mitochondrial membrane depolarization. The expression ratio of Bax to Bcl-2 mRNA correlates with apoptotic cell death. Additionally, encapsulation of the one Ru(II)-Cu(II) complex in bilosomes significantly improved its stability, selectivity, and therapeutic efficacy in three-dimensional (3D) cancer spheroid models.
本研究报告了四种新型含膦 - 氟喹诺酮共轭物的异核Ru(II)-Cu(II)配合物的合成、表征及生物学评价。利用X射线衍射、密度泛函理论计算和各种光谱技术进行的结构分析证实了其稳定性和配位几何结构。在多种癌细胞系(肺癌、乳腺癌、胰腺癌、前列腺癌)和非癌细胞中进行了体外细胞毒性评估。还使用斑马鱼幼虫模型评估了体内毒性。结果表明,与顺铂相比,Ru(II)-Cu(II)配合物表现出更强的抗癌活性,而在体外对对照细胞几乎无毒。机理研究表明,它们的作用涉及细胞核积累、活性氧生成、脂质过氧化和线粒体膜去极化。Bax与Bcl-2 mRNA的表达比率与凋亡细胞死亡相关。此外,将一种Ru(II)-Cu(II)配合物包裹在双分子层脂质体中,在三维(3D)癌症球体模型中显著提高了其稳定性、选择性和治疗效果。
Front Bioeng Biotechnol. 2024-7-11
Cell Commun Signal. 2024-7-5
Biochem Biophys Res Commun. 2024-6-18
Pharmacol Res. 2024-3
Biomed Pharmacother. 2024-2
Biomed Pharmacother. 2024-2